Today's Low
₹ 98.05
Today's High
₹ 99.75
52 Weeks Low
₹ 63.35
52 Weeks High
₹ 106.40
Lower
₹ 81.00
Upper
₹ 121.50
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2011 | FY 2010 | FY 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 228.2 | 184.6 | 164.2 | 157.4 | 183.1 | 184.8 | 164.6 | 143.0 | 105.1 | 95.1 | 80.9 | 69.2 | 61.4 |
Total Non-Current Assets | 82.9 | 76.0 | 75.9 | 81.0 | 78.3 | 75.4 | 68.8 | 68.0 | 58.7 | 59.6 | 54.4 | 55.0 | 55.3 |
Total Assets | 311.0 | 260.5 | 240.1 | 238.4 | 261.3 | 260.2 | 233.3 | 211.0 | 163.9 | 154.7 | 135.3 | 124.2 | 121.7 |
Total Current Liabilities | 209.3 | 165.7 | 152.5 | 159.5 | 163.2 | 154.4 | 143.2 | 111.2 | 92.4 | 86.8 | 34.6 | 27.8 | 31.5 |
Total Non-Current Liabilities | 38.0 | 36.4 | 34.2 | 33.6 | 37.9 | 45.6 | 30.0 | 45.1 | 16.3 | 17.9 | 64.5 | 60.7 | 53.0 |
Shareholder's Funds | 63.8 | 58.6 | 53.6 | 52.4 | 66.6 | 65.0 | 62.5 | 54.9 | 55.2 | 50.1 | 36.2 | 35.8 | 37.2 |
Total Liabilities | 311.0 | 260.5 | 240.1 | 238.4 | 261.3 | 260.2 | 233.3 | 211.0 | 163.9 | 154.7 | 135.3 | 124.2 | 121.7 |
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 0.57, which results in a Negative aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 0.99, which results in a Negative aspect.
The Industry Price to BV stands at 6.03, vs the Price to BV of 2.38, which results in a Negative aspect.
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 2.26, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2011 | FY 2010 | FY 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 304.2 | 281.2 | 250.5 | 171.1 | 225.0 | 209.3 | 228.9 | 198.3 | 187.2 | 178.9 | 114.3 | 106.2 | 103.6 |
Total Expenditure | 279.0 | 257.2 | 225.9 | 166.1 | 207.3 | 192.0 | 214.1 | 183.5 | 170.1 | 161.0 | 104.4 | 101.0 | 93.1 |
Operating Profit(Excl OI) | 26.2 | 29.1 | 25.8 | 6.9 | 18.7 | 19.1 | 17.9 | 16.1 | 18.3 | 18.5 | 10.7 | 8.2 | 10.7 |
Add: Other Income | 0.9 | 5.2 | 1.1 | 1.9 | 1.0 | 1.7 | 3.0 | 1.3 | 1.2 | 0.7 | 0.8 | 2.9 | 0.1 |
Operating Profit | 26.2 | 29.1 | 25.8 | 6.9 | 18.7 | 19.1 | 17.9 | 16.1 | 18.3 | 18.5 | 10.7 | 8.2 | 10.7 |
Less: Interest | 12.3 | 10.9 | 12.2 | 12.7 | 12.7 | 9.4 | 8.5 | 6.5 | 6.5 | 7.2 | 6.8 | 6.3 | 4.7 |
PBDT | 13.9 | 18.2 | 13.6 | -5.9 | 6.0 | 9.7 | 9.4 | 9.7 | 11.8 | 11.4 | 3.9 | 2.0 | 5.9 |
Less: Depreciation Amortization | 9.1 | 9.0 | 9.5 | 7.7 | 6.2 | 6.8 | 6.5 | 7.0 | 7.0 | 4.7 | 2.9 | 2.9 | 1.9 |
PBT & Exceptional Items | 4.8 | 9.2 | 4.1 | -13.5 | -0.2 | 2.9 | 2.9 | 2.7 | 4.7 | 6.6 | 1.0 | -0.9 | 4.1 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | 4.8 | 9.2 | 4.1 | -13.5 | -0.2 | 2.9 | 2.9 | 2.7 | 4.7 | 6.6 | 1.0 | -0.9 | 4.1 |
Less: Taxation | 2.1 | 3.5 | -0.6 | -0.6 | -2.4 | 2.5 | 3.3 | 2.4 | 1.2 | 1.6 | 0.6 | 0.5 | 1.1 |
Profit After Tax | 2.6 | 5.7 | 4.7 | -12.9 | 2.2 | 0.4 | -0.4 | 0.3 | 3.6 | 5.1 | 0.4 | -1.4 | 3.0 |
Earnings Per Share | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry PAT Margin stands at 9.77, vs the PAT Margin of -7.53, which results in a Negative aspect.
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 43.44, which results in a Positive aspect.
The Industry PAT Growth stands at 32.18, vs the PAT Growth of -698.78, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 1.03, which results in a Positive aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2011 | FY 2010 | FY 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 4.7 | 9.2 | 4.1 | -13.5 | -0.2 | 2.9 | 2.9 | 2.6 | 4.7 | 6.6 | 1.0 | -0.9 | 4.1 |
Tax Paid | -0.5 | -1.2 | -0.1 | -0.2 | -2.4 | -1.3 | -1.4 | -0.8 | -1.3 | -1.2 | 0.2 | -0.7 | -1.0 |
Adjustment | 21.4 | 17.2 | 21.1 | 19.0 | 17.4 | 15.1 | 14.8 | 11.5 | 11.7 | 10.4 | 9.5 | 7.1 | 6.6 |
Changes In Working Capital | 4.7 | 9.2 | 4.1 | -13.5 | -0.2 | 2.9 | 2.9 | 2.6 | 4.7 | 6.6 | 1.0 | -0.9 | 4.1 |
Cash Flow after changes in Working Capital | -1.3 | 28.0 | 22.4 | 23.4 | 10.1 | 1.8 | 7.7 | -18.6 | 15.8 | 14.5 | 4.4 | -4.5 | 13.9 |
Cash Flow from Operating Activities | -1.8 | 26.8 | 22.3 | 23.2 | 7.8 | 0.6 | 6.3 | -19.4 | 14.5 | 13.3 | 4.6 | -5.2 | 12.9 |
Cash Flow from Investing Activities | -22.2 | -9.5 | -5.5 | -4.7 | -8.0 | -3.6 | -8.0 | -13.9 | -5.3 | -7.3 | -1.6 | 4.6 | -11.3 |
Cash Flow from Financing Activities | 24.4 | -17.2 | -16.6 | -20.0 | 0.0 | 3.5 | -5.9 | 32.4 | -6.8 | -7.5 | -2.4 | 0.7 | -3.0 |
Net Cash Inflow / Outflow | 0.4 | 0.1 | 0.2 | -1.4 | -0.3 | 0.5 | -7.6 | -0.9 | 2.4 | -1.5 | 0.6 | 0.1 | -1.4 |
Opening Cash & Cash Equivalents | 1.1 | 1.0 | 0.9 | 2.4 | 2.7 | 2.2 | -17.7 | 5.5 | 3.0 | 4.5 | 1.6 | 1.5 | 2.9 |
Closing Cash & Cash Equivalent | 1.5 | 1.1 | 1.0 | 0.9 | 2.4 | 2.7 | -25.3 | 4.6 | 5.5 | 3.0 | 2.2 | 1.6 | 1.5 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of 224.05, which results in a Positive aspect.
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of 1.98, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 816.6 | 925.4 | 703.9 | 824.5 | 766.2 | 753.1 | 698.4 | 740.5 | 691.7 | 671.7 | 708.3 | 630.3 | 645.6 | 521.3 | 337.7 | 431.7 |
Total Income | 817.6 | 926.9 | 705.4 | 826.4 | 770.8 | 753.6 | 700.8 | 777.5 | 699.2 | 677.3 | 709.6 | 632.2 | 646.2 | 522.9 | 349.5 | 435.8 |
Total Expenditure | 738.7 | 848.5 | 639.4 | 742.9 | 704.7 | 695.3 | 648.1 | 706.0 | 629.5 | 608.5 | 633.4 | 571.0 | 574.6 | 470.5 | 331.4 | 424.7 |
PBIDT (Excl OI) | 78.0 | 77.0 | 64.4 | 81.6 | 61.5 | 57.7 | 50.3 | 34.5 | 62.2 | 63.3 | 74.9 | 59.3 | 71.0 | 50.8 | 6.3 | 7.0 |
Other Income | 1.0 | 1.4 | 1.6 | 1.9 | 4.6 | 0.5 | 2.4 | 37.0 | 7.5 | 5.6 | 1.4 | 1.9 | 0.6 | 1.6 | 11.7 | 4.1 |
Operating Profit | 78.9 | 78.4 | 66.0 | 83.5 | 66.1 | 58.2 | 52.8 | 71.5 | 69.7 | 68.8 | 76.2 | 61.2 | 71.6 | 52.4 | 18.1 | 11.1 |
Interest | 36.6 | 38.2 | 36.4 | 38.5 | 31.1 | 28.6 | 23.7 | 24.5 | 23.6 | 26.3 | 29.7 | 28.9 | 31.9 | 27.9 | 30.2 | 28.1 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 42.3 | 40.2 | 29.7 | 45.0 | 35.0 | 29.7 | 29.1 | 47.0 | 46.1 | 42.6 | 46.5 | 32.3 | 39.8 | 24.5 | -12.2 | -16.9 |
Depreciation | 29.6 | 24.2 | 25.3 | 20.9 | 24.5 | 23.7 | 22.3 | 24.2 | 22.1 | 22.1 | 21.9 | 20.3 | 21.7 | 18.8 | 35.9 | 14.2 |
Profit Before Tax | 12.7 | 16.0 | 4.3 | 24.1 | 10.5 | 6.0 | 6.8 | 22.8 | 24.0 | 20.5 | 24.6 | 12.0 | 18.1 | 5.7 | -48.0 | -31.1 |
Tax | 4.2 | 6.3 | 3.4 | 7.9 | 4.6 | 4.7 | 4.0 | 0.9 | 19.3 | 6.5 | 8.1 | 8.0 | 13.1 | 2.9 | -0.7 | 6.0 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 8.5 | 9.7 | 1.0 | 16.2 | 5.9 | 1.3 | 2.8 | 21.9 | 4.7 | 14.0 | 16.5 | 4.0 | 5.0 | 2.8 | -47.4 | -37.1 |
Net Profit | 8.5 | 9.7 | 1.0 | 16.2 | 5.9 | 1.3 | 2.8 | 21.9 | 4.7 | 14.0 | 16.5 | 4.0 | 5.0 | 2.8 | -47.4 | -37.1 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 158.0 | 156.9 | 156.9 | 156.9 | 156.9 | 155.7 | 148.2 | 148.2 | 148.2 | 148.2 | 148.2 | 141.7 | 141.7 | 141.7 | 141.7 | 141.7 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 0.5 | 0.6 | 0.1 | 1.0 | 0.4 | 0.1 | 0.2 | 1.3 | 0.3 | 1.0 | 1.1 | 0.2 | 0.3 | 0.3 | -3.3 | -2.6 |
Operating Profit Margin | 9.7 | 8.5 | 9.4 | 10.1 | 8.6 | 7.7 | 7.6 | 9.7 | 10.1 | 10.2 | 10.8 | 9.7 | 11.1 | 10.1 | 5.4 | 2.6 |
Net Profit Margin | 1.0 | 1.0 | 0.1 | 2.0 | 0.8 | 0.2 | 0.4 | 3.0 | 0.7 | 2.1 | 2.3 | 0.6 | 0.8 | 0.5 | -14.0 | -8.6 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of -23.96, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -53.83, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 105.90 | 110.25 | 99.96 |
R3 | 104.02 | 103.85 | 98.83 |
R2 | 102.13 | 102.05 | 98.45 |
R1 | 99.92 | 99.75 | 98.08 |
Pivot | 98.03 | 97.95 | 98.03 |
S1 | 95.82 | 95.65 | 97.32 |
S2 | 93.93 | 93.85 | 96.95 |
S3 | 91.72 | 91.55 | 96.57 |
S4 | 89.50 | 85.65 | 95.45 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
73.43
Neutral
RSI
42.19
Neutral
ROC
-1.20
Bearish
UltimateOscillator
40.72
Neutral
Williams Indicator
-45.71
Neutral
CCI Indicator
-29.63
Neutral
MACD
-2,849.13
Bearish
Stochastic Indicator
55.34
Neutral
ATR
5.02
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
18-09-2023 | 1.00 | 10 | Final |
13-09-2022 | 1.00 | 10 | Final |
16-09-2021 | 1.00 | 10 | Final |
Date Of Conduct | Board Meeting Details |
---|---|
12-02-2024 | Quarterly Results |
08-11-2023 | Employees Stock Option Plan & Quarterly Results |
11-08-2023 | Quarterly Results & A.G.M. |
29-05-2023 | Audited Results & Final Dividend |
06-02-2023 | Quarterly Results |
14-11-2022 | Quarterly Results(Cancelled) |
11-08-2022 | Quarterly Results |
30-05-2022 | Final Dividend & Audited Results |
13-04-2022 | Preferential Issue of shares |
09-03-2022 | Inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd , subject to the approval of applicable statutes and shareholders of the Company. |
10-02-2022 | Quarterly Results |
11-11-2021 | Quarterly Results |
10-08-2021 | Quarterly Results |
29-06-2021 | A.G.M. & Audited Results & Final Dividend |